RO 20-1724 (29925-17-5) is a selective inhibitor of cAMP-specific phosphodiesterase (PDE4), IC50 = 0.2 μM. Displays anti-inflammatory activity. Cell permeable
Ro 20-1724 is a cell-permeable, cAMP-specific phosphodiesterase type IV (PDE4) inhibitor (IC50 = 2 μM). It weakly inhibits PDE3 with a Ki value greater than 25 μM. Ro 20-1724 inhibits the release of cytokines and other inflammatory signals as well as prevents the development of reactive oxygen species. It is often used to study cAMP-related functions in vascular cells.
Ro 20-1724 Is an inhibitor of phosphodiesterase-4, and also very effective for patients with plaque psoriasis. Selective inhibitor of cAMP-specific phosphodiesterase. Selective PDE4 inhibitor.
ChEBI: 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone is a member of methoxybenzenes.
Widely used inhibitor of cyclic nucleotide phosphodiesterase, selective for PDE4 (IC 50 = 2.0 μ M). Also available as part of the Phosphodiesterase Inhibitor Tocriset™ .
Inhibitor of cAMP phosphodiesterase. IC50 33 μM in vascular smooth muscle of the aorta.
1) Soderling et al. (1998), Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase; Proc. Natl. Acad. Sci. USA, 95 8991
2) Nicholson et al. (1991), Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes; Trends Pharmacol. Sci., 12 19
